3billion
3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as … Read more
3billion - Asset Resilience Ratio
3billion (394800) has an Asset Resilience Ratio of 69.05% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how 3billion's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down 3billion's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩10.70 Billion | 32.84% |
| Short-term Investments | ₩11.80 Billion | 36.21% |
| Total Liquid Assets | ₩22.50 Billion | 69.05% |
Asset Resilience Insights
- Very High Liquidity: 3billion maintains exceptional liquid asset reserves at 69.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
3billion Industry Peers by Asset Resilience Ratio
Compare 3billion's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for 3billion (2021–2024)
The table below shows the annual Asset Resilience Ratio data for 3billion.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 77.65% | ₩23.46 Billion | ₩30.22 Billion | +4.45pp |
| 2023-12-31 | 73.20% | ₩16.73 Billion | ₩22.86 Billion | -9.12pp |
| 2022-12-31 | 82.32% | ₩22.77 Billion | ₩27.66 Billion | +24.04pp |
| 2021-12-31 | 58.28% | ₩12.00 Billion | ₩20.59 Billion | -- |